Mr. Andre Larente reports

DIAGNOS INC. ANNOUNCES GRANT OF STOCK OPTIONS AND ADOPTION OF SEMI-ANNUAL REPORTING

Diagnos Inc. has granted an aggregate number of 1.5 million stock options to directors and officers of the corporation.

The date of the grant is June 11, 2026. The expiry date to which the stock options can be exercised is June 11, 2031. Stock options vest at 50 per cent per year, commencing with the first anniversary of the grant. The exercise price of the stock options granted has been established at 20 cents per common share. The grant remains subject to regulatory compliance including TSX Venture Exchange acceptance.

The corporation is also announcing that, as of the date of this press release and until further notice, it is voluntarily adopting semi-annual reporting under the semi-annual report pilot of the Canadian Securities Administrators. The SAR pilot provides an exemption for eligible issuers from the requirement to file first and third quarter financial reports under National Instrument 51-102 (Continuous Disclosure Obligations). The corporation is in the opinion that adopting semi-annual reporting will make financial reporting more efficient and cost-effective.

Finally, further to the press release dated Jan. 15, 2026, the corporation did not retain the services of Investor Brand Network to provide corporate communication and awareness solutions to the corporation.

About Diagnos Inc.

Diagnos is a publicly traded Canadian corporation dedicated to early detection of critical eye-related health problems. By leveraging artificial intelligence, Diagnos aims to provide more information to health care clinicians to enhance diagnostic accuracy, streamline workflows and improve patient outcomes on a global scale.

We seek Safe Harbor.